Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigator-initiated Clinical Trial of MIKE-1 (MIKE-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05064618
Recruitment Status : Recruiting
First Posted : October 1, 2021
Last Update Posted : October 1, 2021
Sponsor:
Collaborator:
Japan Agency for Medical Research and Development
Information provided by (Responsible Party):
Hiroki Kawashima, Nagoya University

Brief Summary:
To evaluate the safety and tolerability of Am80(Generic name: Tamibarotene, Development code: MIKE-1) in combination with gemcitabine (GEM) and nab-paclitaxel (nab-PTX) in patients with unresectable pancreatic cancer and to determine the recommended dose. Efficacy will also be exploratively investigated.

Condition or disease Intervention/treatment Phase
Pancreatic Cancer Drug: Am80 Phase 1 Phase 2

Detailed Description:

Cancer-associated fibroblasts (CAFs) are an important component of the tumor microenvironment. The most common notion in the CAF research field has been that CAFs promote cancer progression through various mechanisms. Interestingly, however, recent studies have revealed that CAFs are heterogeneous and that CAF subsets that suppress cancer progression (cancer-restraining CAFs [rCAFs]) must exist in addition to well-characterized cancer-promoting CAFs (pCAFs). However, the identity and specific markers of rCAFs have not been reported.

The investigators recently identified Meflin as a specific marker protein of rCAFs in pancreatic and colon cancers. The investigator's studies revealed that rCAFs are similar to a small subset of resident fibroblasts, which is consistent with the famous hypothesis proposed by Micheal Stoker (University of Glasgow) more than 50 years ago, stating that static normal fibroblasts suppress tumor growth. Interestingly, The investigator's lineage tracing experiments showed that Meflin-positive rCAFs differentiate into Meflin-negative pCAFs during cancer progression. These studies revealed that the tumor stroma is comprised of pCAFs and rCAFs, which is analogous to the heterogeneity of tumor-infiltrating immune cells (e.g., protumor regulatory T cells versus antitumor cytotoxic T cells).

The identification of the rCAF marker Meflin enabled the investigators to develop new strategies to convert or reprogram pCAFs to rCAFs. Using a pharmacological approach, The investigators performed a chemical library screen and identified Am80, a synthetic unnatural retinoid, as a reagent that effectively converts Meflin-negative pCAFs to Meflin-positive rCAFs. Am80 administration improved the sensitivity of pancreatic cancer to chemotherapeutics. These data suggested that the conversion of pCAF to rCAFs may represent a new strategy for pancreatic cancer treatment.

The object of this study is to perform an investigator-initiated clinical study to investigate the effect of AM80 on pancreatic cancer with a combination of conventional tumoricidal agents including gemcitabine and nab-paclitaxel.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 55 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Groups of participants are assigned to receive interventions based on prior milestones being reached in the study, such as in some dose escalation and adaptive design studies.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Investigator-initiated Clinical Trial of MIKE-1 With Gemcitabine and Nab-paclitaxel Combination Therapy for Unresectable Pancreatic Cancer
Actual Study Start Date : August 23, 2021
Estimated Primary Completion Date : April 30, 2025
Estimated Study Completion Date : April 30, 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Phase I study; 3+3 Design

Phase I study; single-center, open-label, uncontrolled, dose-finding study

  • MIKE-1 (AM80, Tamibarotene) After the DLT assessment period, if there is no evidence of disease progression or unacceptable toxicity to the patient according to RECIST v1.1, the investigational drug in each dose group will continue to be administered orally twice daily after breakfast and dinner for up to 24 weeks.The dose of the study drug will not be reduced or increased in the same subject.

    • 6 mg dose group (level 1).
    • 8 mg dose group (level 2).
    • 4 mg group (level 0). To be considered when two or more cases of DLT occur at level 1.
  • GEM/nab-PTX (Phase I / II study) GEM (1000mg/m2) and nab-PTX (125mg/m2) will be administered intravenously.
Drug: Am80
medicine taken internally
Other Names:
  • Tamibarotene
  • MIKE-1

Experimental: Phase II study; Single-centre, open-label, single arm, uncontrolled study.
The dose of MIKE-1 will be fixed at the clinically recommended dose determined in Phase I. MIKE-1 will be administered orally twice daily after breakfast and dinner, and treatment will be continued until the occurrence of intolerable toxicity or disease progression, up to a maximum of six courses, to confirm efficacy and safety (tolerability).
Drug: Am80
medicine taken internally
Other Names:
  • Tamibarotene
  • MIKE-1




Primary Outcome Measures :
  1. Phase I study; DLT (dose-limiting toxicity) [ Time Frame: The DLT evaluation period is from Day 1, the start date of study drug administration, to Day 28 of Phase I study. ]

    The severity of adverse events will be determined by the investigator based on CTCAE v 5.0.

    • Grade 4 hematologic toxicity that persists for more than 7 days
    • Grade 3 or higher non-hematologic toxicity that persists for more than 7 days despite symptomatic treatment
    • An adverse event that caused the inability to administer both Day 8 and Day 15 of Cycle 1 of GEM or nab-PTX
    • An adverse event that caused the inability to administer Day 8 of the first cycle of GEM or nab-PTX, resulting in a reduced dose of Day 15

  2. Phase II study; response rate (based on RECIST ver1.1) [ Time Frame: through phase II study completion,an average of half year. ]
    If each subject has measurable disease, tumor shrinkage efficacy determination (CR, PR, SD, PD, NE) will be performed based on RECIST v1.1.


Secondary Outcome Measures :
  1. AE(Adverse events) [ Time Frame: All of the clinical trial period (up to 6 cycles, 28 days per cycle) ]
    Adverse events will be classified and tabulated in MedDRA/J.

  2. OS(Overall survival) [ Time Frame: The time from the date of first dose of MIKE-1 until date of death from any cause. The cut-off date is the end of post-observation for all patients. ]
    The distribution of overall survival will be estimated by the Kaplan-Meier method, the Kaplan-Meier curve will be illustrated, and the median and 95% confidence interval will be calculated.

  3. PFS(Progression-free survival) [ Time Frame: The time from date of first dose of MIKE-1 to date of first documentation of disease progression or death, whichever occurs. The cut-off date is the end of post-observation for all patients. ]
    The distribution of progression-free survival will be estimated by the Kaplan-Meier method, the Kaplan-Meier curve will be illustrated, and the median and 95% confidence interval will be calculated.

  4. Area under the blood concentration time curve (AUC) [ Time Frame: 1, 2, 4, 8, 10, and 24 hours after first dosing in phase I. ]
    Calculate summary statistics

  5. Peak Plasma Concentration (Cmax) [ Time Frame: 1, 2, 4, 8, 10, and 24 hours after first dosing in phase I. ]
    Calculate summary statistics

  6. Elimination half-life (t1/2) [ Time Frame: 1, 2, 4, 8, 10, and 24 hours after first dosing in phase I. ]
    Calculate summary statistics

  7. Clearance (CL) [ Time Frame: 1, 2, 4, 8, 10, and 24 hours after first dosing in phase I. ]
    Calculate summary statistics

  8. Mean residence time (MRT) [ Time Frame: 1, 2, 4, 8, 10, and 24 hours after first dosing in phase I. ]
    Calculate summary statistics

  9. Volume of distribution (Vds) [ Time Frame: 1, 2, 4, 8, 10, and 24 hours after first dosing in phase I. ]
    Calculate summary statistics

  10. Response rate (Phase I) [ Time Frame: All of the clinical trial period (up to 6 cycles, 28 days per cycle) ]
    Based on RECIST ver1.1



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  • Inclusion Criteria:

    - Patients who meet all of the following criteria will be eligible for this study. Besides, CTCAE v5.0 will be used to determine the grade of adverse events in this study.

    1. Patients with unresectable pancreatic cancer who are histologically or cytologically diagnosed as adenocarcinoma based on the 7th edition of the Pancreatic Cancer Treatment Protocol and meet the following criteria.

      Patients who have not received any anticancer therapy (radiation therapy, chemotherapy, immunotherapy, surgery, or investigational therapy) for this disease.

    2. Patients who are between 20 and 79 years of age at the time of consent.
    3. Patients with at least one measurable lesion based on RECIST ver 1.1 in the primary pancreatic lesion confirmed by contrast-enhanced CT at the screening.
    4. Patients who are expected to survive for at least 12 weeks after the start of treatment.
    5. Patients who can understand the contents of this study and can give written consent.
    6. Patients with ECOG PS (Eastern Cooperative Oncology Group Performance Status) of 0 or 1
    7. Patients who meet the following criteria in blood tests within 7 days before enrollment and whose organ functions are preserved (if blood transfusion is used, tests must be performed at intervals of at least 2 weeks afterward)

      • Total bilirubin ≤ upper limit of institutional standard (ULN) x 1.5 (less than or equal to 3.0 mg/dL for patients undergoing ERBD or PTBD)
      • AST (GOT) and ALT (GPT) ≦ ULN × 3 (In the case of abnormal liver function due to malignancy, ≤ ULN × 5)
      • Creatinine ≤ 1.5 mg/dL or
      • Creatinine clearance ≥ 60ml/min If creatinine clearance is not measured, the estimated value should be used.
      • White blood cell count ≥ 3,500/mm3, ≤ 12,000/mm3
      • Neutrophils ≥ 1,500/mm3
      • Platelet count ≥ 100,000/mm3
      • Hemoglobin ≥ 9.0g/dL
      • Prothrombin activity level ≥ 70%
    8. Outpatients who can go to the hospital.
    9. Patients who can swallow or continue to take oral medications.
    10. For women of childbearing potential, patients who can use contraception for at least 30 days before the start of study treatment, during the study period, and for at least 2 years after the end of treatment.
    11. Patients who can undergo biopsy from pancreatic cancer ①within 28 days before the start of the study treatment and ② 8 weeks after the start of the study treatment (Day 57: acceptable range: ±7 days)
  • Exclusion Criteria:

    1. Patients with any of the following complications Patients with poorly controlled heart disease (congestive heart failure, myocardial infarction, or unstable angina within 1 year before enrollment, arrhythmia requiring treatment, etc.) Poorly controlled diabetes or hypertension Active autoimmune disease requiring systemic administration of steroids or immunosuppression therapy Interstitial pneumonia or pulmonary fibrosis (patients with current grade 2 or higher)
    2. Patients who have received other clinical trial drugs or products (excluding existing chemotherapeutic agents and placebo drugs) within 4 weeks before enrolment.
    3. Patients with confirmed brain metastasis (confirmed by head CT or MRI if the patient has symptoms of brain metastasis)
    4. Patients with ascites or pleural effusion requiring drainage.
    5. Patients who fall under any of the following HBs antigen positive HCV antibody positive and HCV-RNA positive HIV antibody positive
    6. Patients with Grade 2 or higher peripheral sensory or motor neuropathy
    7. Patients with multiple cancers (multiple cancers are defined as simultaneous multiple cancers and metachronous multiple cancers with disease-free survival of 5 years or less. lesions equivalent to carcinoma in situ or intramucosal carcinoma that are considered curable by local treatment are not included in multiple cancers)
    8. Patients who have undergone surgery (excluding diagnostic biopsy and review laparoscopy) within 4 weeks before enrollment.
    9. Patients with bleeding disorders or coagulation disorders that preclude the safe biopsy under EUS (e.g., significant intratumoral bleeding, coagulation disorders, history of bleeding disorders, or complications).
    10. Patients with a history of allergy to the trial drug, combination chemotherapy, its additives, or vitamin A products.
    11. Patients requiring anticoagulant medication.
    12. Patients with cerebral infarction, pulmonary infarction, other arterial or venous thrombosis or its sequelae with clinical symptoms.
    13. Patients with gastrointestinal disorders that may affect the absorption of the investigational drug.
    14. Female patients who are pregnant or breastfeeding (unless breastfeeding is discontinued and not resumed).
    15. Male patients whose sex partner is a woman who wishes to become pregnant.
    16. Patients with vitamin A overload.
    17. Patients receiving vitamin A preparations or regularly using vitamin A-containing supplements (patients can be enrolled if the administration is discontinued at the time of obtaining consent).
    18. Other patients deemed inappropriate by the investigator or sub-investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05064618


Contacts
Layout table for location contacts
Contact: Yasuyuki Mizutani +81-52-741-2111 y-mizu@med.nagoya-u.ac.jp
Contact: Toshihisa Tsuruta +81-52-741-2111 ttsuruta@med.nagoya-u.ac.jp

Locations
Layout table for location information
Japan
Nagoya University Hospital Recruiting
Nagoya, Aich, Japan, 466-8560
Contact: Yasuyuki Mizutani    +81-52-741-2111    y-mizu@med.nagoya-u.ac.jp   
Contact: Tsuruta Toshihisa    +81-52-741-2111    ttsuruta@med.nagoya-u.ac.jp   
Sponsors and Collaborators
Nagoya University
Japan Agency for Medical Research and Development
Investigators
Layout table for investigator information
Principal Investigator: Hiroki Kawashima Nagoya University
Additional Information:
Publications:
Layout table for additonal information
Responsible Party: Hiroki Kawashima, Associate Professor, Nagoya University
ClinicalTrials.gov Identifier: NCT05064618    
Other Study ID Numbers: CAMCR-016
jRCT2041210056 ( Registry Identifier: jRCT )
First Posted: October 1, 2021    Key Record Dates
Last Update Posted: October 1, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Hiroki Kawashima, Nagoya University:
Am80
Meflin
Cancer-associated fibroblasts
Tamibarotene
ISLR
Cancer-restraining CAFs
Cancer-promoting CAFs
MIKE-1
Vitamin A
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases